BackAcceleron Pharma Overview

Acceleron Pharma Other Liabilities

Track Acceleron Pharma's other liabilities ($370K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$373000.00

Peer average

Loading

Acceleron Pharma Other Liabilities History

Loading

Acceleron Pharma vs. peers: Other Liabilities Comparison

Loading

Acceleron Pharma Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Acceleron Pharma (XLRN) FAQ

Acceleron Pharma (XLRN) currently reports a other liabilities of $370K as of September 2021. In the prior-year period, the figure was $0. Use the charts on this page to explore Acceleron Pharma's other liabilities history and peer comparisons.

Acceleron Pharma's other liabilities changed from $0 to $370K (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acceleron Pharma reported $370K in other liabilities as of September 2021. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $370K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acceleron Pharma, and consider following XLRN for alerts when major investors trade the stock.

Acceleron Pharma is classified in the Healthcare sector. On other liabilities, it currently shows $370K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XLRN with unrelated industries.